Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Revitalizing monoamine oxidase inhibitors: a call for action.

Gillman PK, Feinberg SS, Fochtmann LJ.

CNS Spectr. 2019 Jul 5:1-3. doi: 10.1017/S1092852919001196. [Epub ahead of print] No abstract available.

PMID:
31272520
2.

A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Gillman PK.

J Neural Transm (Vienna). 2018 Nov;125(11):1707-1717. doi: 10.1007/s00702-018-1932-y. Epub 2018 Sep 25. Review.

PMID:
30255284
3.

Patient Safety and Methylene Blue-Associated Severe Serotonin Toxicity.

Rosenbaum HK, Gillman PK.

A A Case Rep. 2016 Jul 1;7(1):1. doi: 10.1213/XAA.0000000000000314. No abstract available.

PMID:
27415030
4.

Fatal methylene blue associated serotonin toxicity.

Top WM, Gillman PK, de Langen CJ, Kooy A.

Neth J Med. 2014 Apr;72(3):179-81.

5.

'Withdrawal neuroleptic malignant syndrome': a phantom explanatory cause for a fatality.

Gillman PK.

Med Sci Law. 2011 Apr;51(2):122-3; author reply 124. No abstract available.

PMID:
21793478
6.

Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors.

Gillman PK.

J Clin Psychopharmacol. 2011 Feb;31(1):66-74. doi: 10.1097/JCP.0b013e31820469ea. Review.

PMID:
21192146
7.

Methylene blue and serotonin toxicity: definite causal link.

Gillman PK.

Psychosomatics. 2010 Sep-Oct;51(5):448-9. doi: 10.1176/appi.psy.51.5.448. No abstract available.

PMID:
20833947
8.

Neuroleptic malignant syndrome: half a century of uncertainty suggests a Chimera.

Gillman PK.

Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):876-7. doi: 10.1002/pds.2008. No abstract available.

PMID:
20665596
9.

Neuroleptic malignant syndrome: mechanisms, interactions, and causality.

Gillman PK.

Mov Disord. 2010 Sep 15;25(12):1780-90. doi: 10.1002/mds.23220. Review.

PMID:
20623765
10.

More on Mrs Murphy's beans: or "Do us a fava".

Gillman PK.

J Clin Psychopharmacol. 2010 Apr;30(2):215-6. doi: 10.1097/JCP.0b013e3181d47f8c. No abstract available.

PMID:
20520305
11.

Neuroleptic malignant syndrome, poor science and inaccurate measurements.

Gillman PK.

J Psychopharmacol. 2011 Jun;25(6):850. doi: 10.1177/0269881110367461. Epub 2010 May 20. No abstract available.

PMID:
20488833
12.

Bupropion, bayesian logic and serotonin toxicity.

Gillman PK.

J Med Toxicol. 2010 Jun;6(2):276-7. doi: 10.1007/s13181-010-0084-8. No abstract available.

13.

The nature of hyperthermia in neuroleptic malignant syndrome and the use of bromocriptine.

Gillman PK.

J Med Toxicol. 2010 Jun;6(2):272-3. doi: 10.1007/s13181-010-0069-7. No abstract available.

14.

CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity.

Gillman PK.

J Psychopharmacol. 2011 Mar;25(3):429-36. doi: 10.1177/0269881109359098. Epub 2010 Feb 8. Review.

PMID:
20142303
15.

Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review.

Gillman PK.

Headache. 2010 Feb;50(2):264-72. doi: 10.1111/j.1526-4610.2009.01575.x. Epub 2009 Nov 17. Review.

PMID:
19925619
16.

Lessons continue: serotonin toxicity.

Gillman PK.

Consult Pharm. 2009 Jul;24(7):474-6; author reply 476-7. No abstract available.

PMID:
19694109
17.

Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity.

Schwiebert C, Irving C, Gillman PK.

Anaesthesia. 2009 Aug;64(8):924. doi: 10.1111/j.1365-2044.2009.06029.x. No abstract available.

18.

Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity?

Gillman PK.

Am J Emerg Med. 2009 May;27(4):509-10; author reply 510. doi: 10.1016/j.ajem.2009.03.001. No abstract available.

PMID:
19555629
19.

Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium.

Stanford SC, Stanford BJ, Gillman PK.

J Psychopharmacol. 2010 Oct;24(10):1433-8. doi: 10.1177/0269881109105450. Epub 2009 May 7. Review.

PMID:
19423610
20.

Methylene blue is a potent monoamine oxidase inhibitor.

Gillman PK.

Can J Anaesth. 2008 May;55(5):311-2; author reply 312. No abstract available.

PMID:
18451123

Supplemental Content

Loading ...
Support Center